Analyst consensus rating
BridgeBio Oncology Therapeutics Analyst Rating: none
Direct answer
BridgeBio Oncology Therapeutics's consensus rating is none.
11 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $24.55.
Forecast evidence checked October 3, 2026.
Get free BridgeBio Oncology Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $3.89
- Average price target
- $24.55
- High price target
- $50.00
- Low price target
- $15.00
- Low target gap
- +285.6%
- Target upside
- +531%
- High target gap
- +1,185.3%
- Target range width
- 899.7%
- Consensus rating
- none
- Analysts
- 11
- Evidence date
- October 3, 2026
- Valid through
- October 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for BridgeBio Oncology Therapeutics?
BridgeBio Oncology Therapeutics has a verified none consensus. The same dataset has an average price target of $24.55.
How far are BridgeBio Oncology Therapeutics's low and high targets from the recorded price?
The low target implies +285.6%, while the high target implies +1,185.3%.
How many analysts are included in BridgeBio Oncology Therapeutics's consensus?
The verified consensus includes 11 analysts.
How is BridgeBio Oncology Therapeutics's target upside or downside calculated?
The average target of $24.55 is divided by the recorded price of $3.89, then one is subtracted to produce +531%. This does not guarantee a future return.
When was BridgeBio Oncology Therapeutics's analyst forecast verified?
The data was verified on 2026-10-03. The dataset is valid through 2026-10-10.